focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,747.00
Bid: 1,746.50
Ask: 1,747.50
Change: -28.00 (-1.58%)
Spread: 1.00 (0.057%)
Open: 1,770.00
High: 1,770.00
Low: 1,747.00
Prev. Close: 1,775.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

Wed, 03rd Jan 2024 07:54

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

This is also ahead of two key data releases in the US later, particularly the latest meeting minutes from the US Federal Reserve this evening, which will provide investors insight into the central bank's thinking on the future of US interest rates.

Prior to this, the Institute of Supply Management's manufacturing PMI for the US is released in the afternoon.

"Markets turned cautious ahead of today's [Federal Open Market Committee] minutes, US JOLT's job openings number, and the ISM manufacturing index. Markets have rallied over the past few weeks, and the dollar has come under considerable pressure as markets price in six rate cuts by the Fed this year," said TreasuryOne analyst Andre Cilliers.

"The Fed is only forecasting three cuts at this stage, and we saw some short dollar covering yesterday while bonds and equities were sold off."

In UK corporate news, both Wizz Air and Ryanair reported increased passenger numbers in December and across 2023.

Here is what you need to know at the London market open:

----------

MARKETS

----------

FTSE 100: called down 1.0 point at 7,720.52

----------

Hang Seng: down 1.4% at 7,523.20

Nikkei 225: financial markets in Japan closed for New Year holiday

S&P/ASX 200: closed down 1.4% at 7,523.20

----------

DJIA: closed up 25.50 points, or 0.1%, at 37,715.04

S&P 500: closed down 27.00 points, or 0.6%, at 4,742.83

Nasdaq Composite: closed down 245.41 points, or 1.6%, to 14,765.94

----------

EUR: up at USD1.0959 (USD1.0955)

GBP: up at USD1.2635 (USD1.2620)

USD: up at JPY142.34 (JPY141.74)

Gold: down at USD2,062.16 per ounce (USD2,064.66)

(Brent): down at USD75.81 a barrel USD77.75)

(changes since previous London equities close)

----------

ECONOMICS

----------

Wednesday's key economic events still to come:

09:55 CET Germany unemployment

10:00 EST US ISM manufacturing PMI

14:00 EST US Federal Reserve meeting minutes

----------

The Israeli army has said it is "prepared for any scenario" after a strike in Beirut that killed Hamas's deputy chief, stoking fears the war in the Gaza Strip could boil over into wider regional conflict. Israeli army spokesperson Daniel Hagari did not directly comment on the killing, but said afterwards that the military was in "very high state of readiness in all arenas, in defence and offence. We are highly prepared for any scenario." Israel has previously announced the deaths in Gaza of Hamas commanders and officials during the war, but Aruri is the most high-profile figure to be killed, and his death came in the first strike on the Lebanese capital since hostilities began.

----------

BROKER RATING CHANGES

----------

Jefferies cuts AstraZeneca to 'hold' (buy) - price target 11,000 (12,500) pence

----------

Jefferies raises GSK to 'buy' (hold) - price target 1,900 (1,550) pence

----------

COMPANIES - FTSE 250

----------

Wizz Air said it carried 5.0 million passengers in December, up 19% from a year earlier, at a load factor of 82% from 85%. Across 2023, it carried 60.3 million passengers, up 32% from 45.7 million in 2022, at a load factor of 91% from 87%. Capacity in December rose 22% to 6.0 million passengers from 5.0 million a year earlier, while across 2023, capacity rose 26% to 66.4 million from 52.7 million. The airline said it continued to grow its network and improve its customer offering in December, including Wizz Air Abu-Dhabi doubling the number of flights to 15,000 and carrying more than three million passengers.

----------

OTHER COMPANIES

----------

Budget airline Ryanair said it carried 12.5 million passengers in December, up 8.7% from 11.5 million passengers a year earlier, at a load factor of 91% from 92%. It said it operated over 72,500 flights in December, while over 900 flights were cancelled due to the Israel/Gaza conflict. Across 2023, it carried 181.8 million passengers, up 13% from 160.4 million in 2022, at a load factor of 94% from 92%.

----------

Drug discovery company C4X Discovery said it has received a milestone payment of USD11 million from FTSE 100-listed pharmaceutical firm AstraZeneca, triggered by pre-clinical progress of C4X Discovery's NFT2 Activator programme. AstraZeneca is developing C4X Discovery's former programme to deliver an oral therapy for the treatment of inflammatory and respiratory diseases, with a lead focus on chronic respiratory disease. As announced under the terms of the licencing agreement in November 2022, C4X Discovery received an initial USD2 million upfront payment from AstraZeneca and is potentially entitled to receive up to USD400 million in preclinical, clinical development and commercial milestones, as well as tiered mid-single digit royalties on future sales. C4X Discovery Clive Dix commented: "This significant preclinical milestone payment marks the progress AstraZeneca has made in driving the NRF2 Activator programme forward. NRF2 is a challenging target and this achievement provides further validation of our ability to generate differentiated, quality molecules in immuno-inflammation."

----------

Chill Brands unveiled product launch plans and regulatory initiatives for the first quarter of 2024. As previously announced, the CBD products company received a number of material purchase orders during the fourth quarter of 2023. It is now in the process of fulfilling those purchase orders and expects to have delivered all initial inventory during January 2024. Chill ZERO nicotine-free vape products will launch into initial WH Smith travel locations, Morrisons stores, and roadside retail stores operating on Shell, BP and Esso branded forecourts during January 2024 with the rollout continuing incrementally throughout the first quarter. Chill Brands said it will also take steps to address regulatory concerns on balancing the "positive impact of vaping as a harm reduction tool with the need to protect children and the environment". It plans to do this by participating in a recycling scheme, to focus on "appropriate merchandising and age verification to ensure express compliance with existing and future regulations at all points of the supply chain", and to use more "conscious" design and flavour choices that indicate its products are "solely intended for adult consumers".

----------

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
18 Dec 2023 17:21

Energy stocks lift UK's FTSE 100, Vodafone shines

Vodafone jumps as Iliad offers to merge Italian units

*

Read more
18 Dec 2023 10:07

GSK's dostarlimab trial in endometrial cancer meets primary endpoint

(Alliance News) - GSK PLC on Monday said a trial of dostarlimab in combination with niraparib for treating endometrial cancer has met its primary endpoint.

Read more
18 Dec 2023 07:55

LONDON BRIEFING: Games Workshop seals Amazon deal for Warhammer 40,000

(Alliance News) - Stocks in London were set to retreat slightly on Monday, in line with equity markets in Asia, at the start of the last week before the Christmas holidays.

Read more
18 Dec 2023 07:18

GSK sees success in Jemperli endometrial cancer trial

(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.

Read more
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.